Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Feedback extends CDC contract for Sussex ICS development programme

Published 06/09/2022, 08:18
Updated 06/09/2022, 09:12
© Reuters.  Feedback extends CDC contract for Sussex ICS development programme

Feedback PLC (LON:FDBK) (AIM:FDBK), the clinical infrastructure company, said it was awarded a 12-month contract to provide its Community Diagnostic Centre (CDC) solution to allow for an extension of a pilot in Sussex alongside Queen Victoria Hospital (QVH).

The extension of the pilot phase of the Sussex Health and Care Partnership Integrated Care System (Sussex ICS) development programme will test the current CDC solution, which is used to create faster access to diagnostic testing to reduce waiting times.

In a statement, Feedback said the discounted contract is valued at £450,000 and covers the period from 31 March 2022, when the previous agreement ended, until 31 March 2023.

Additionally, by the end of the contract, the company expects QVH to have “concluded a formal procurement for the next phase of the CDC programme”, where Feedback intends to bid.

Feedback said the contract comes as the first live patients go through the CDC pilot, which was set up to establish symptom-based pathway models for CDC services using Feedback's digital infrastructure solutions Bleepa and CareLocker. The deployment of Feedback's product suite in the Sussex ICS is intended to be used as a blueprint model for future CDC digital infrastructure models across the UK, it noted.

"QVH and the broader Sussex team have been great partners in delivering this end-to-end clinical solution,” said chief executive of Feedback Dr Tom Oakley.

“This contract recognises the initial stage of our work together and enables us to proceed to a more formal working arrangement, pending a successful procurement exercise.”

Read more on Proactive Investors UK

Disclaimer

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.